MTOR and breast cancer: In conclusion, whilst it is clear that many ER-positive BC patients do well with endocrine therapy alone [14], [22], recent clinical trial data presented in the ER-positive metastatic BC setting provide substantial support for mTOR pathway activation as a major means of estrogen independent tumor growth in this population [6], [23].